Arcus Biosciences AI Stock Analysis
Want to see RCUS full AI Analyst Report?
Arcus Biosciences (RCUS) AI Stock Analysis
Arcus Biosciences
(NYSE:RCUS)
The score is held down primarily by weak financial performance (large and worsening losses plus heavy cash burn) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Offsetting factors include a constructive earnings call with defined clinical catalysts and stated runway into H2 2028, alongside supportive corporate events (capital raise and positive ARC-20 data), but these do not fully counterbalance the current profitability and cash flow risks.
Arcus Biosciences Key Performance Indicators (KPIs)
Revenue by SegmentBreaks down revenue by different business units or product lines, highlighting which areas are driving growth and which may need strategic adjustments.
Revenue is clearly lumpy and milestone-driven: large, infrequent license/development receipts drive the peaks while “Other Collaboration” provides a small, shrinking baseline—so GAAP revenue is timing-dependent, not recurring. Management’s reiterated $50–65M guidance and strong cash runway ease financing concerns, but planned R&D cuts and portfolio focus on cascadifan mean baseline collaboration receipts may decline. In short, treat near-term revenue as binary milestone noise tied to partner payments and clinical catalysts (PEEK‑1/other readouts), not as evidence of durable commercial traction.
Arcus Biosciences (RCUS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.25B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.85M
- Price to Earnings (P/E)
- -4.3
- Beta (1Y)
- 1.42
- Revenue Growth
- -58.33%
- EPS Growth
- -6.14%
- Country
- US
- Employees
- 601
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Arcus Biosciences Business Overview & Revenue Model
Company Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney ca...
How the Company Makes Money
Arcus Biosciences does not primarily generate revenue from commercial product sales because, as a clinical-stage company, it has not historically relied on approved, marketed drugs as a core earnings base (commercial product revenue information: null...
Arcus Biosciences Earnings Call Summary
The call emphasized multiple substantial clinical and business positives: strong translational validation (Nature paper), robust development progress for casdatifan with clear registrational timelines (PEAK‑1 enrollment on track and PEAK‑20 planned), multiple strategic collaborations, a broad immunology pipeline with near‑term IND milestones (AB102, TNFR1), and a solid cash runway into H2 2028. Key near‑term risks include a meaningful quarter‑over‑quarter cash reduction (~11.5%), expected declines in collaboration revenue from the Gilead wind‑down, high R&D spend with planned concentration (>80%) on casdatifan by 2027, and dependence on upcoming clinical readouts to validate the growth and revenue thesis. On balance, the highlights — clinical progress, partnerships, translational evidence, and adequate runway — outweigh the lowlights, which are primarily financial/timing and execution risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management provided specific near- and medium-term guidance: as of June 30, 2026 Arcus had $775M cash and investments (down from $876M at March 31), expects to end 2026 with ~ $600M and to have runway into at least H2 2028; Q2 GAAP revenue was $41M with full-year 2026 GAAP revenue guided to $65–75M; Q2 R&D expense was $113M (net) with R&D expected to meaningfully decline in 2026–27 and >80% of 2027 portfolio spend directed to casdatifan, G&A was $24M and non-cash stock‑based comp $15M in Q2. Clinical and commercial timelines: PEAK‑1 (cas + cabozantinib) remains on track to complete enrollment by year‑end 2026, PEAK‑20 (first‑line registrational trial) to start by year‑end 2026, ARC‑20 will deliver a broad October data package from >200 patients (including a first‑line cas+zim cohort with 30 patients and a 7% primary progression rate, a cas+zim ORR readout with ~11 months follow‑up, a second‑line cas+cabo cohort of ~45 patients with ≥18 months follow‑up, and ~120 late‑line monotherapy patients with ~28 months median follow‑up), PRISM‑1 (quemliclustat in pancreatic cancer) is expected to read out in H1 next year, AB102 dosing begins this month with PK data in Q4 and a TNFR1 program entering clinic in early 2027. Finally, market and value context: Arcus projects RCC sales in major markets to reach ~$13B by 2030, estimates PEAK‑1 addresses ~20,000 IO‑experienced patients (> $2B opportunity), first‑line > $4B, and total peak sales opportunity for casdatifan of $5–10B.
Arcus Biosciences Financial Statement Overview
Summary
Fundamentals are weak: revenue is down (~14.5% TTM) while operating losses are very large (TTM operating loss ~$475M) and widening, and cash burn is substantial (TTM operating cash flow and FCF both around -$465M). Balance sheet leverage is moderate (debt-to-equity ~0.28), but equity has fallen meaningfully and returns remain sharply negative, underscoring ongoing financing dependence.
Income Statement
22NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 100.00M | 247.00M | 258.00M | 117.00M | 112.00M | 383.00M |
| Gross Profit | 95.00M | 237.00M | 258.00M | 117.00M | 112.00M | 383.00M |
| EBITDA | -412.00M | -335.00M | -269.00M | -291.00M | -258.00M | 59.00M |
| Net Income | -445.00M | -353.00M | -283.00M | -307.00M | -267.00M | 53.00M |
Balance Sheet | ||||||
| Total Assets | 818.00M | 1.14B | 1.15B | 1.09B | 1.34B | 1.59B |
| Cash, Cash Equivalents and Short-Term Investments | 630.00M | 981.00M | 978.00M | 759.00M | 1.01B | 499.31M |
| Total Debt | 116.00M | 112.00M | 60.00M | 11.00M | 120.00M | 121.99M |
| Total Liabilities | 460.00M | 508.00M | 665.00M | 633.00M | 688.00M | 750.45M |
| Stockholders Equity | 358.00M | 631.00M | 485.00M | 462.00M | 657.00M | 841.45M |
Cash Flow | ||||||
| Free Cash Flow | -466.00M | -484.00M | -176.00M | -330.00M | 432.00M | -282.25M |
| Operating Cash Flow | -465.00M | -482.00M | -170.00M | -306.00M | 438.00M | -256.17M |
| Investing Cash Flow | 66.00M | 66.00M | -84.00M | 194.00M | -413.00M | -3.87M |
| Financing Cash Flow | 312.00M | 488.00M | 277.00M | 33.00M | 33.00M | 237.34M |
Arcus Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RCUS, the sentiment is Negative. The current price of 15.62 is below the 20-day moving average (MA) of 17.76, below the 50-day MA of 21.47, and below the 200-day MA of 24.34, indicating a bearish trend. The MACD of -1.58 indicates Positive momentum. The RSI at 28.58 is Positive, neither overbought nor oversold. The STOCH value of 1.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RCUS.
Arcus Biosciences Risk Analysis
Arcus Biosciences disclosed 61 risk factors in its most recent earnings report. Arcus Biosciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksArcus Biosciences Peers Comparison
Overall Rating
LEGN63Neutral
NRIX61Neutral
XNCR61Neutral
IMCR60Neutral
RCUS48Neutral
CRSP42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 63Neutral | $3.12B | -1525.00 | -0.02% | ― | 49.73% | 98.75% | |
| 61Neutral | $1.49B | 5.12 | 49.34% | ― | 738.76% | ― | |
| 61Neutral | $2.55B | -21.18 | -21.29% | ― | 33.55% | 11.51% | |
| 60Neutral | $1.38B | -41.73 | -7.96% | ― | 13.01% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $2.27B | -4.27 | -90.04% | ― | -58.33% | -6.14% | |
| 42Neutral | $3.78B | -8.25 | -25.59% | ― | -34.34% | 14.92% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RCUS | Arcus Biosciences | 15.62 | -7.56 | -32.61% | |
| XNCR | Xencor Inc. | 33.26 | 16.52 | 98.69% | |
| CRSP | Crispr Therapeutics | 39.10 | -12.15 | -23.71% | |
| LEGN | Legend Biotech Corporation | 15.25 | -11.90 | -43.83% | |
| NRIX | Nurix Therapeutics, Inc. | 12.85 | -4.30 | -25.07% | |
| IMCR | Immunocore Holdings Plc | 26.41 | -12.28 | -31.74% |
Arcus Biosciences Corporate Events
Arcus Biosciences Completes $269 Million Common Stock Offering
PositiveOn October 21, 2026, Arcus Biosciences, Inc. entered into an underwriting agreement with a syndicate of investment banks for a public offering of its common stock at a price of $17.50 per share, including an option for underwriters to purchase additi...
Arcus Biosciences unveils promising kidney cancer data
PositiveOn October 20, 2026, Arcus Biosciences reported new data from its ARC-20 platform study of casdatifan-based regimens in clear cell renal cell carcinoma, covering first-, second- and late-line settings as of a September 4, 2026 cutoff. First-line TKI-...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
